<DOC>
	<DOCNO>NCT01570803</DOCNO>
	<brief_summary>Recent stent design improvement focus decrease stent fracture rate negatively impact patency rate rearrange strut alignment . Although several retrospective registry study atherosclerotic femoropopliteal disease East , randomize control trial comparison stent fracture primary patency different nitinol stent . Smart stent peak-to-valley bridge in-line interconnection . Medtronics company claim Complete 's stent crown configure minimize crown crown interaction , increase stent 's flexibility without compromise radial strength . We make hypothesis design Complete-SE stent might fracture-resistant effective in-stent restenosis , compare Smart stent . On hand , 2011 ESC guideline recommend dual antiplatelet therapy aspirin thienopyridine least one month recommend infrainguinal bare-metal-stent implantation . Recent meta-analysis show efficacy cilostazol atherosclerotic femoropopliteal lesion proven . However , still specific data regard variety antiplatelet regimen limit . To date , study comparison clopidogrel cilostazole patient undergone stent implantation femoropopliteal lesion . In conclusion , purpose study examine compare Primary patency stent fracture different two-nitinol stent ( S.M.A.R.T . CONTROL versus Complete SE ) compare binary restenosis rate clopidogrel cilostazol femoropopliteal arterial lesion .</brief_summary>
	<brief_title>Efficacy Between Different Two Self-Expanding Nitinol Stents For The Atherosclerotic Femoro-Popliteal Arterial Disease</brief_title>
	<detailed_description>Five randomize , control trial fail demonstrate benefit stainless-steel stent angioplasty alone . The nitinol stent proven superior primary patency balloon angioplasty superficial femoral artery ( SFA ) lesion . Several study report stent fracture associate high risk in-stent restenosis reocclusion . In vitro , Stefan et al . report 7 different SFA stent show difference incidence high strain zone , indicate potential stent fracture , demonstrate mechanical fatigue test . They claim difference stent design might play major role appearance stent strut fracture relate restenosis reocclusion . Also , retrospective study , Iida et al . report significant difference stent fracture S.M.A.R.T . stent group Luminexx stent group primary patency worse associate stent fracture without stent fracture . Recent stent design improvement focus decrease stent fracture rate negatively impact patency rate rearrange strut alignment . The design self-expandible nitinol stent might different depend developed time ; The first-generation nitinol stent ( e.g. , LuminexxTM SmartTM ) show remarkably high rate stent strut fracture . A second generation slot tube nitinol stent develop . These stent good flexibility , reduce number connection cell crown , configurating spiral orientation interconnection . Several study report nitinol stent fracture-resistant flexible , provide superior patency rate ( e.g. , LifeTM EverflexTM ) . However , one important limitation study non-randomized study relative small sample size confine in-vitro . Upto date , multicenter , randomize control trial direct comparison stent fracture primary patency two different nitinol stent do except one study ; SMART versus Luminexx stent . SMART Luminexx stent classify 1st generation self-expandable nitinol stent . Complete-SE stent Medtronic company different Smart stent Cordis company configuration interconnection Complete-SE stent peak-to-peak connection spiral orientation interconnection , compare mart stent . On hand , Smart stent peak-to-valley bridge in-line interconnection . Medtronics company claim Complete 's stent crown configure minimize crown crown interaction , increase stent 's flexibility without compromise radial strength . We make hypothesis design Complete-SE stent might fracture-resistant effective in-stent restenosis , compare Smart stent . On hand , date , previous many report , dual antiplatelet therapy consist aspirin clopidogrel proven decrease incidence cardiovascular death , myocardial infarction , revascularization without increase major bleed patient underwent percutaneous coronary intervention regardless stent type ( bare metal stent drug-eluting stent ) . In 2011 ESC ( European society cardiology ) guideline , dual antiplatelet therapy aspirin thienopyridine least one month recommend infra-inguinal bare metal stent implantation ( Class I , Level C ) . However , definite evidence guideline optimal antiplatelet agent stent implantation one month later . There many study efficacy thienopyridine peripheral arterial disease . Also , With potential benefit cilostazol vascular function vitro , several previous effort prove efficacy cilostazol patient undergo endovascular therapy stent implantation peripheral arterial disease . However , still specific data regard variety antiplatelet regimen limit . Also , trial effectively properly address direct comparison efficacy safety clopidogrel cilostazol . This trial design evaluate efficacy safety aspirin plus clopidogrel versus aspirin plus cilostazol patient undergoing stent implantation femoropopliteal lesion .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Clinical criterion 1 . Age 20 year old 2 . Symptomatic peripheralartery disease ( Rutherford 2 6 ) ; moderate severe claudication ( Rutherford 23 ) , chronic critical limb ischemia pain rest ( Rutherford 4 ) , ischemic ulcer ( Rutherford 56 ) 3 . Patients sign informed consent Anatomical criterion 1 . Stenosis &gt; 50 % occlusive atherosclerotic lesion ipsilateral femoropopliteal artery 2 . Patent ( ≤50 % stenosis ) ipsilateral iliac artery concomitantly treatable ipsilateral iliac lesion ( ≤30 % residual stenosis ) , 3 . At least one patent ( le 50 % stenosed ) tibioperoneal runoff vessel . 1 . Disagree write informed consent 2 . Major bleed history within prior 2 month 3 . Known hypersensitivity contraindication follow medication : heparin , aspirin , clopidogrel , cilostazol , contrast agent 4 . Acute limb ischemia 5 . Previous bypass surgery stenting ipsilateral femoropopliteal artery 6 . Untreated inflow disease ipsilateral pelvic artery ( 50 % stenosis occlusion ) 7 . Patients major amputation ( `` ankle '' amputation ) do , plan require 8 . Patients life expectancy &lt; 1 year due comorbidity</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>peripheral arterial disease ,</keyword>
	<keyword>atherosclerosis ,</keyword>
	<keyword>nitinol ,</keyword>
	<keyword>stent</keyword>
</DOC>